&ldquo Wei; Zexi event ” let the immune therapy in the face of many Crusade, member of the CPPCC National Committee, the Xuanwu Hospital Department of Neurosurgery director Ling Feng pointed out, now the study of cellular immunity work throughout the country are stagnant or slow, “ we can see the whole world in the study of cellular immune therapy, the therapy has been recognized as the following fourth major therapy tumor surgery, chemotherapy, radiotherapy. ”

No one can stop the progress of science and technology. In recent years, it is the immunotherapy that has brought cancer therapy into a new era. The scientific and commercial circles have expressed great interest in the application of immunotherapy in the field of cancer. In the 2016 cancer progress report, immunotherapy was a single show. In a few years, several different immunotherapy had entered the clinic from the laboratory.

Due to its excellent efficacy and creativity, tumor immunotherapy was named the most important scientific breakthrough in the year in 2013 by science. Tumor immunotherapy is the principle and method of application of immunology, improve the immunogenicity of tumor cells and the killing effect on sensitivity of cells, stimulate and enhance anti-tumor immune response, and application of immune cells and molecular effects of infusion of host immune system, synergistic killing tumor and inhibiting tumor growth. Because the immunotherapy of tumor is the immune system itself, it can be used in different tumor treatments in theory.

The methods of immunotherapy are also developing. The central link of these immunotherapy is T cells. One of the immunotherapy is CAR-T cell therapy. This method is to collect T cells from patients, reengineer them through genetic engineering, and then retransmit them to patients. Recombinant T cells produce special proteins that enable T cells to detect and attack cancer cells in the body.

At present, the successful cases of CAR-T therapy are only in the field of blood cancer, and solid tumors such as breast cancer and lung cancer are still in the early stage of research.

Combined treatment is a trend in the future

Tumor heterogeneity is the biggest obstacle in the clinical treatment of tumor. Different tumors have different targets, and the target point of tumor therapy is highly specific. CAR-T cell therapy according to the main target for the design, through the &ldquo encoding; heavy ” patients with T cells, activate the immune cells, stimulate the body's immune system, generate a large number of tumor specific CAR-T cells, specific removal of tumor cells, has the advantages of high specificity, long period effect and low side effect etc. CAR-T, cell therapy is considered the ultimate way to cure the tumor.

Although CAR-T is a new hope for cancer, there are still problems. For example, the safety of CAR-T, the requirement of CAR-T treatment for tumor target is high, but many tumors do not find a specific target. So CAR-T treatment is easy to cause damage to normal cells, and its curative effect is almost the same as chemotherapy. The research and development of CAR-T needs to be combined with clinical practice, and it also needs to be combined with clinical design in the design of CAR-T.

The field of immunological oncology is still in the early stages of development, but new therapies and new drugs have followed. From the current point of view, combination therapy is one of the inevitable trend of the future development of immunotherapy, but how to make the combination (with united together, or what medication before and after medication), efficacy and toxicity to patients, combination therapy can take the price, all these problems need to be solved. According to the analysis of the industry, the combined treatment of targeted drugs and immunological antitumor drugs will be widely used in the next 6 years. In the first few years, targeted combined immunotherapy for breast cancer and hematological tumors will take the lead. After 2018, the targeted combination therapy of solid tumors, such as lung cancer and melanoma, will be progressed by leaps and bounds.

.